Back to Search
Start Over
Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns.
- Source :
-
Vaccines [Vaccines (Basel)] 2021 Nov 03; Vol. 9 (11). Date of Electronic Publication: 2021 Nov 03. - Publication Year :
- 2021
-
Abstract
- Present mass vaccination against Coronavirus Disease-19 (COVID-19) is the most widely used health policy and the most promising approach to curb the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic globally. However, new side effects are emerging from the mass vaccination not described during the experimental stages. In the present study, we discuss a case of acute corneal graft rejection, which has occurred 25 years after transplantation and 13 days after the administration of the BNT162b2 vaccine (Comirnaty, BioNTech/Pfizer), which was followed-up for a period of six months. In this period, the corneal inflammation appeared twice but was successfully managed with topical therapy and supplementation of Vitamin D. A risk of corneal graft rejection must be included in the list of potential vaccine complications, in order to inform the transplanted patient to undergo a preliminary and a follow-up ocular examination, and eventually to include corneal graft in the list of contraindications to vaccination.
Details
- Language :
- English
- ISSN :
- 2076-393X
- Volume :
- 9
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Vaccines
- Publication Type :
- Report
- Accession number :
- 34835205
- Full Text :
- https://doi.org/10.3390/vaccines9111274